Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
7.98 | 1.14% | 0.09 |
AQST closed up 1.14 percent on Thursday, December 13, 2018, on 1.15 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| See historical AQST trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 13 | Spinning Top | Other | 0.00% |
| Dec 13 | Narrow Range Bar | Range Contraction | 0.00% |
| Dec 13 | NR7 | Range Contraction | 0.00% |
| Dec 13 | Wide Bands | Range Expansion | 0.00% |
| Dec 13 | Oversold Stochastic | Weakness | 0.00% |
| Dec 12 | Wide Bands | Range Expansion | 1.14% |
| Dec 12 | Oversold Stochastic | Weakness | 1.14% |
| Dec 11 | NR7 | Range Contraction | -6.99% |
| Dec 11 | Wide Bands | Range Expansion | -6.99% |
| Dec 11 | Oversold Stochastic | Weakness | -6.99% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AQST news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 20.7 |
| 52 Week Low | 7.47 |
| Average Volume | 115,301 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 13.7262 |
| 20-Day Moving Average | 10.6255 |
| 10-Day Moving Average | 8.289 |
| Average True Range | 1.1737 |
| ADX | 39.69 |
| +DI | 10.7451 |
| -DI | 31.724 |
| Chandelier Exit (Long, 3 ATRs ) | 14.5439 |
| Chandelier Exit (Short, 3 ATRs ) | 10.9911 |
| Upper Bollinger Band | 17.2076 |
| Lower Bollinger Band | 4.0434 |
| Percent B (%b) | 0.3 |
| BandWidth | 123.892523 |
| MACD Line | -1.9562 |
| MACD Signal Line | -1.8927 |
| MACD Histogram | -0.0635 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.49 | ||||
| Resistance 3 (R3) | 8.48 | 8.29 | 8.41 | ||
| Resistance 2 (R2) | 8.29 | 8.16 | 8.30 | 8.38 | |
| Resistance 1 (R1) | 8.14 | 8.08 | 8.22 | 8.15 | 8.35 |
| Pivot Point | 7.95 | 7.95 | 7.99 | 7.96 | 7.95 |
| Support 1 (S1) | 7.80 | 7.82 | 7.88 | 7.81 | 7.61 |
| Support 2 (S2) | 7.61 | 7.74 | 7.62 | 7.58 | |
| Support 3 (S3) | 7.46 | 7.61 | 7.56 | ||
| Support 4 (S4) | 7.47 |
